BMC NEUROSCIENCE is a prominent open access journal dedicated to the dissemination of high-quality research within the dynamic and rapidly evolving field of neuroscience. Published by BMC, a well-respected leader in open access publishing, this journal facilitates the free exchange of knowledge since its inception in 2000. With the ISSN 1471-2202, BMC NEUROSCIENCE aims to address the diverse interests of the neuroscience community by covering a broad spectrum of topics, ranging from cellular and molecular neuroscience to general neurological studies, thus appealing to researchers, professionals, and students alike. Although it currently holds a Q4 ranking in Cellular and Molecular Neuroscience and a Q3 rank in miscellaneous Neuroscience categories, its commitment to advancing the understanding of brain function and disorders remains steadfast. The journal features a user-friendly Open Access model, ensuring that critical research findings are readily accessible to everyone, fostering collaboration and innovation in the field. As the journal continues to evolve towards its convergence years of 2024, it aspires to enhance its impact and global reach, making it a valuable resource for anyone interested in advancing neuroscience research.

NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

LIFE SCIENCES, published by PERGAMON-ELSEVIER SCIENCE LTD, is an esteemed international journal that has been advancing the field since its inception in 1962. With an ISSN of 0024-3205 and an E-ISSN of 1879-0631, it serves as a critical forum for researchers, professionals, and students within the realms of biochemistry, genetics, molecular biology, medicine, and pharmacology. Currently ranked in the Q1 category across multiple disciplines, including a remarkable 2nd rank in General Pharmacology, Toxicology, and Pharmaceutics, the journal maintains a prestigious position in academic circles, evidenced by its high impact factor and significant percentile ranks. While LIFE SCIENCES is not an open-access journal, it remains dedicated to publishing high-quality, peer-reviewed research that pushes the boundaries of knowledge and fosters innovation. With converged research interests leading into 2024, LIFE SCIENCES continues to be a pivotal resource for the dissemination of influential findings, making it an indispensable tool for those engaged in the life sciences.

Welcome to the Korean Journal of Physiology & Pharmacology, a pivotal academic platform dedicated to advancing the disciplines of physiology and pharmacology. Published by the esteemed Korean Journal of Physiology & Pharmacology, this journal has been disseminating valuable research findings since its inception in 1997 and continues to be a critical resource for researchers, professionals, and students in South Korea and beyond. With an ISSN of 1226-4512 and E-ISSN of 2093-3827, it offers insights into various aspects of drug action and physiological mechanisms. Although this journal currently does not subscribe to Open Access, it plays a vital role in bridging the gap between experimental and clinical studies, receiving commendations for its quality. In the 2023 Scopus rankings, it is notably positioned in the Q3 quartile for Pharmacology and Q4 for Physiology, reflecting its commitment to excellence. As the journal converges towards its comprehensive coverage in 2024, it remains a cornerstone for those looking to engage deeply with critical developments in these fields.

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

Physiology and Pharmacology is a distinguished open access journal that has been disseminating high-quality research in the fields of physiology and pharmacology since its inception in 1997. Published by the Iranian Society of Physiology & Pharmacology, this journal offers a platform for scholars and practitioners to share innovative findings and advancements that contribute to the understanding of biological systems and drug action. With its ISSN 2476-5236 and E-ISSN 2476-5244, it ensures global reach and accessibility. The journal is positioned in the third quartile for Linguistics and Language and fourth quartile in both Pharmacology and Physiology categories according to Scopus rankings, reflecting a commitment to expanding knowledge within these interdisciplinary domains. Set within the academic landscape of Iran, the journal aims to bridge regional research with the international community, providing valuable insights into physiological processes and pharmacological developments. In light of its open access model, the Physiology and Pharmacology journal plays a crucial role in enhancing the visibility of research outcomes and fostering collaboration among researchers, professionals, and students on a global scale.

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

Journal of Neuroinflammation is a premier open-access journal published by BMC that has been at the forefront of research in the field since its inception in 2004. With a strong focus on the intricate interplay between the nervous system and immune responses, this journal aims to create a forum for the dissemination of high-quality research that informs our understanding of neuroinflammation and its implications in neurological disorders. Positioned in the top quartile across multiple categories including Cellular and Molecular Neuroscience, Immunology, and Neurology, the journal ranks impressively within the Scopus database, ensuring visibility to the global research community. The Journal of Neuroinflammation provides a vital platform for researchers and professionals to share groundbreaking findings, methodologies, and reviews that advance science and foster collaboration. With its commitment to open access, the journal ensures that its content is accessible to a broad audience, enhancing the dissemination of knowledge in this critical field of study.

Advances in Pharmacology and Pharmacy is a pioneering journal devoted to the dissemination of cutting-edge research in the fields of pharmacology and pharmaceutical sciences. Published by Horizon Research Publishing, this peer-reviewed journal boasts a commitment to advancing knowledge and innovation, making it an essential resource for researchers, industry professionals, and students alike. With an ISSN of 2332-0036 and an E-ISSN of 2332-0044, it provides a platform for high-quality research articles that explore new therapeutic approaches, drug development strategies, and the regulatory aspects of pharmaceutical science. Although currently lacking a formal impact factor, the journal's emphasis on open access ensures that articles are widely available, promoting the sharing of valuable insights and collaborative efforts in the scientific community. Located at 506 N Garfield Ave, Ste 210, Alhambra, CA 91801, the journal welcomes contributions from diverse areas within pharmacology and pharmacy, reinforcing its significance as a vital resource in the ever-evolving landscape of pharmaceutical research.